Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 9312345...102030...Last »

AstraZeneca’s Diabetes Drug Farxiga Decreases Risk of Cardiovascular Disease

AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).

Read More »

Amarin’s Fish Oil-Based Drug Dramatically Reduces Cardiovascular Risk

In Amarin’s REDUCE-IT clinical trial of 8,179 statin-treated adults with increased risk of cardiovascular problems, the drug showed a 25 percent relative risk reduction in major adverse cardiovascular events compared to placebo.

Read More »

CDC: 14 Million Americans Will Have Alzheimer’s by 2060

Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.

Read More »

Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis

Celltrion Inc. signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

Read More »

AstraZeneca’s Asthma Drug Looks Good in Multiple Late-Stage Trials

AstraZeneca released positive results from the BORA Phase III extension clinical trial of Fasenra (benralizumab) as an add-on maintenance therapy in patients with severe eosinophilic asthma that had already completed either the SIROCCO or CALIMA Phase III trials.

Read More »

Zealand Pharma’s Phase III Severe Hypoglycemia Rescue Treatment Hits the Mark in Clinical Trial

Denmark-based Zealand Pharma announced that the company’s Phase III trial for dasiglucagon for severe insulin-induced hypoglycemia in diabetes hit all primary and key secondary endpoints, setting up potential regulatory approval.

Read More »

Allergan and Sosei Halt Alzheimer’s Study

Allergan and the company’s development partner Sosei Group voluntarily suspended clinical trials of HTL0018318 in Alzheimer’s and other types of dementia because of safety problems.

Read More »

Viking shares surge after fatty liver drug trial

Viking Therapeutics Inc.’s shares more than doubled in value after promising data from a mid-stage trial of the company’s fatty liver drug were seen as topping that from larger rival Madrigal Pharmaceuticals.

Read More »

AstraZeneca Plans to Seek Regulatory Approval for COPD Drug PT010 Following Phase III Trial

Following a setback in a chronic obstructive pulmonary disease (COPD) clinical trial in August, AstraZeneca unveiled data from a separate trial that showed the triple combination therapy PT010 outperformed dual-therapy rivals eight of nine times.

Read More »

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates, and western pharmaceutical companies are making greater inroads there.

Read More »

Half of Europe’s clinical trials fail to report results

Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.

Read More »

Doctors offer advice for insomnia

People who have trouble falling asleep and staying asleep may want to seek advice from a doctor and avoid long-term use of sleeping pills, medical experts advise.

Read More »

Cancer deaths to rise to 9.6 million in 2018

Cancer will claim the lives of 9.6 million people in 2018, accounting for one in eight of all deaths among men and one in 11 among women, the WHO’s cancer research agency said.

Read More »

Vital Therapies shares dive as liver system fails trial

Vital Therapies Inc. will explore strategic options after the U.S. biotech firm’s liver disease treatment failed to meet the main goal of a late-stage study, driving its shares down more than 70 percent.

Read More »

Galapagos soars on $4-6 billion hopes for new drug

Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Galapagos to an all-time high as analysts forecast multibillion-dollar sales.

Read More »

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

Read More »

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd.’s lead drug for treating moderate-to-severe acne met the main goals of the company’s third late-stage study, sending its shares up 57 percent in extended trading.

Read More »

Amgen’s Aimovig Starts Strong, Multiple Myeloma Drug Wows at Conference

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

Read More »

EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial

EpicGenetics and Massachusetts General Hospital are launching a Phase II clinical trial to test a tuberculosis vaccine, CBG, as a potential treatment for fibromyalgia.

Read More »

Merck KGaA, Pfizer’s immuno-drug shown to alleviate kidney cancer

Merck KGaA said the immunotherapy Bavencio, jointly developed with Pfizer Inc., delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.

Read More »

Page 1 of 9312345...102030...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom